SCLP.L Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 geg. 2024 @ 15:54):

Stats
Dzisiejszy wolumen	732 868
Średni wolumen	395 545
Kapitalizacja rynkowa	89.39M
EPS	£0 ( 2024-01-30 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-9.63
ATR14	£0.154 (1.60%)

Scancell Holdings PLC Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Scancell Holdings PLC Finanse

Annual	2022
Przychody:	£5.27M
Zysk brutto:	£4.75M (90.04 %)
EPS:	£-0.0146

FY	2022
Przychody:	£5.27M
Zysk brutto:	£4.75M (90.04 %)
EPS:	£-0.0146

FY	2022
Przychody:	£0
Zysk brutto:	£0 (0.00 %)
EPS:	£-0.00250

FY	2021
Przychody:	£0.00
Zysk brutto:	£0.00 (0.00 %)
EPS:	£-0.0392

Financial Reports:

No articles found.

Scancell Holdings PLC

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.